# Alzheimer's Tau Platform: Master Protocol

> **NCT06957418** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Paul S. Aisen** · enrollment: 900 (estimated)

## Conditions studied

- Preclinical Alzheimer's Disease
- Alzheimer Disease
- Prodromal Alzheimer's Disease

## Interventions

- **DRUG:** AADvac1
- **DRUG:** Tau2

## Key facts

- **NCT ID:** NCT06957418
- **Lead sponsor:** Paul S. Aisen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2028-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06957418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06957418, "Alzheimer's Tau Platform: Master Protocol". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06957418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*